Dipenkumar Modi
Wayne State University
H-index: 12
North America-United States
Top articles of Dipenkumar Modi
Haploidentical vs Mismatched Unrelated Donor Transplants with Posttransplant Cyclophosphamide-based GVHD Prophylaxis
2024/2/16
Dipenkumar Modi
H-Index: 6
Abhinav Deol
H-Index: 19
Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor …
Transplantation and Cellular Therapy
2024/2/1
Ramzi Abboud
H-Index: 3
Dipenkumar Modi
H-Index: 6
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Nature Medicine
2024/1
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
Leukemia
2023/5
Acute Leukemia and MDS Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those with 60-69 Years of Age
Blood
2023/11/28
Abhinav Deol
H-Index: 19
Dipenkumar Modi
H-Index: 6
Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study …
Blood
2023/11/28
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL …
Blood
2023/11/28
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
Leukemia & Lymphoma
2018/8/3
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world …
Haematologica
2023/11/11
P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
HemaSphere
2023/8/1
Dipenkumar Modi
H-Index: 6
Hematopoietic Stem Cell Transplantation: An Overview
2023/6/15
Dipenkumar Modi
H-Index: 6
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission
Leukemia & Lymphoma
2023/6/7
Dipenkumar Modi
H-Index: 6
Abhinav Deol
H-Index: 19
WAVELINE‐004: OPEN‐LABEL, PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (MK‐2140) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE …
Hematological Oncology
2023/6
OUTCOMES OF AUTOLOGOUS TRANSPLANT, ALLOGENEIC TRANSPLANT, AND CAR T CELL THERAPY IN TP53 ALTERED MANTLE CELL LYMPHOMA: A MULTI‐INSTITUTION RETROSPECTIVE ANALYSIS
Hematological Oncology
2023/6
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
2023/6/1
Dipenkumar Modi
H-Index: 6
An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT).
2023/6/1
Dipenkumar Modi
H-Index: 6
Sojung Kim
H-Index: 1
HLA-Haploidentical Vs Mismatched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis for AML and MDS: Is There a Winner?
Blood
2022/11/15
Dipenkumar Modi
H-Index: 6
Abhinav Deol
H-Index: 19
Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case …
Blood
2022/11/15
Amitkumar Mehta
H-Index: 41
Alvaro J Alencar
H-Index: 9
Dipenkumar Modi
H-Index: 6
Mayur Narkhede
H-Index: 5
Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the …
Blood
2022/11/15
Does Choice of Salvage Regimen Impact Stem Cell Mobilization in Hodgkin's Lymphoma?
Blood
2022/11/15
Dipenkumar Modi
H-Index: 6
Abhinav Deol
H-Index: 19
